HC Wainwright & Co. Reiterates Buy on Regulus Therapeutics, Maintains $9 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Regulus Therapeutics (NASDAQ:RGLS) and maintained a $9 price target.
August 10, 2023 | 8:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regulus Therapeutics (NASDAQ:RGLS) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $9.
The reiteration of the 'Buy' rating and the maintenance of the $9 price target by HC Wainwright & Co. indicates a positive outlook for Regulus Therapeutics. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100